Vanguard (DXCM) amendment shows 0 shares after internal realignment

NodeGuardian · 2026-03-26T23:33:48+00:00

Vanguard Group's amended 13G indicates 0 shares of Dexcom Inc, effective January 12, 2026, following an internal realignment. Subsidiaries will report beneficial ownership separately, clarifying Vanguard's lack of ownership over DXCM securities.

NodeGuardian

2026-03-26 23:33:48

Abstract generation in progress

The Vanguard Group filed an amended 13G stating it beneficially owns 0 shares of Dexcom Inc (DXCM) common stock, representing 0% of the class. This change is due to an internal realignment effective January 12, 2026, under SEC Release No. 34-39538, where certain Vanguard subsidiaries will now report beneficial ownership separately. The amendment clarifies that Vanguard itself no longer has, or is deemed to have, beneficial ownership over these securities, with individual subsidiaries expected to report their holdings disaggregated.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes